期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

靶向治疗时代:减瘤手术在转移性肾癌中的价值 被引量：1

下载PDF
导出
摘要 2005年,索拉非尼的临床应用揭开了靶向药物治疗转移性肾癌（metastatic renal cell carcinoma,mRCC）的新篇章.此后针对不同肿瘤调控靶点的药物如舒尼替尼、贝伐单抗、帕唑帕尼和依维莫司等也相继进入临床.在当今靶向治疗的时代（targetedtherapy era,TTE）,已证实靶向治疗对于无论是肿瘤总生存期（overall survival,OS）亦或无进展生存期（progression-free survival,PFS）及耐受性均优于之前的免疫治疗.为了追求更高的生存期,在免疫治疗时代（immunotherapy era,ITE）广泛应用的减瘤手术（cytoreductive surgery,CRS）仍备受关注,但减瘤手术能否使患者在靶向治疗的背景下获益目前仍是争论的焦点.
作者 魏强
机构地区 四川大学华西医院泌尿外科
出处 《现代泌尿外科杂志》 CAS 2014年第7期484-484,共1页 Journal of Modern Urology
关键词 转移性肾细胞癌 减瘤手术 靶向治疗
分类号 R737.17 [医药卫生—肿瘤]
  • 相关文献

参考文献4

  • 1CONTI SL, THOMAS IC, HAGEDORN JC, et al. Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era[J]. Int J Cancer,2014,134(9) :2245-2252.
  • 2CHOUEIRI TK, XIE W, KOLLMANNSBERGER C, et al. The impact of eytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy[J]. J Urol, 2011,185(1):60-66.
  • 3DABESTANI S, HOFMANN F, MARCONI'L, et al, EAU renal cell carcinoma guideline paneliSt. Systematic review methodology for the EAU RCC Guideline 2013 update. 2013 03-25.
  • 4TRINH QD, BIANCHI M, HANSEN J, et al. In-hospital mortal- ity and failure to rescue after cytoreductive nephrectomy[J]. Eur Urol,2013, 63(6) :1107-1114.

同被引文献34

  • 1BIANCHI M,SUN M,JELDRES C,et al.Distribution of metastatic sites in renal cell carcinoma: a population-based analysis[J].Ann Oncol,2012,23(4):973-980.
  • 2RONCATI L,MAIORANA A.Biological characterization of metastatic renal cell carcinoma [J].Urologia,2010,77(Suppl 16):37-41.
  • 3LEE-YING R,LESTER R,HENG D.Current management and future perspectives of metastatic renal cell carcinoma[J].Int J Urol,2014,21(9):847-855.
  • 4KRABBE LM,HADDAD AQ,WESTERMAN ME,et al.Surgical management of metastatic renal cell carcinoma in the era of targeted therapies[J].World J Urol,2014,32(3):615-622.
  • 5GALAZI M,RODRIGUEZ-VIDA A,JOSEPHIDES E,et al.Cytoreductive nephrectomy: past,present and future[J].Expert Rev Anticancer Ther,2014,14(3):271-277.
  • 6ZINI L,CAPITANIO U,PERROTTE P,et al.Population-based assessment of survival after cytoreductive nephrectomy versus no surgery in patients with metastatic renal cell carcinoma[J].Urology,2009,73(2):342-346.
  • 7FLANIGAN RC,SALMON SE,BLUMENSTEIN BA,et al.Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer[J].N Engl J Med,2001,345(23):1655-1659.
  • 8MICKISCH GH,GARIN A,VAN POPPEL H,et al.Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial[J].Lancet,2001,358(9286):966-970.
  • 9FLANIGAN RC,MICKISCH G,SYLESTER R,et al.Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis[J].J Urol,2004,171(3):1071-1076.
  • 10CHIONG E,WOOD CG,MARGULIS V.Role of cytoreductive nephrectomy in renal cell carcinoma[J].Future Oncol,2009,5(6):859-869.

引证文献1

二级引证文献2

现代泌尿外科杂志
2014年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部